
The spiraling cost of cancer care, in particular the cost of cancer zzso that achieve only marginal benefits, is under increasing zzso Although health-care professionals avoid putting a value on a life, our limited resources require that society address what counts as a benefit, the extent to which cost should factor in deliberations, and who should be involved in these zzso Professional societies, such as the American Society of Clinical zzso government agencies, including the Food and Drug Administration, and insurance companies should be zzso However, no segment of society is better qualified to address these issues than the zzso zzso zzso must offer clear guidance for the conduct of research, interpretation of results, and prescription of zzso We review recent drug approvals and clinical trials and comment on their relevance to the issue of the spiraling cost of zzso zzso We suggest some standards that would serve as a starting point for addressing these zzso 

